Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
To determine whether the presenilin 1 (PS1), presenilin 2 (PS2) and amyloid beta-protein precursor (APP) mutations linked to familial Alzheimer's disease (FAD) increase the extracellular concentration of amyloid beta-protein (A beta) ending at A beta 42(43) in vivo, we performed a blinded comparison of plasma A beta levels in carriers of these mutations and controls. A beta 1-42(43) was elevated in plasma from subjects with FAD-linked PS1 (P < 0.0001), PS2N1411 (P = 0.009), APPK670N,M671L (P < 0.0001), and APPV7171 (one subject) mutations. A beta ending at A beta 42(43) was also significantly elevated in fibroblast media from subjects with PS1 (P < 0.0001) or PS2 (P = 0.03) mutations. These findings indicate that the FAD-linked mutations may all cause Alzhelmer's disease by increasing the extracellular concentration of A beta 42(43), thereby fostering cerebral deposition of this highly amyloidogenic peptide.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Aβ is produced by sequential β- and γ-secretase proteolytic cleavage of the amyloid precursor protein (APP) [11–17].”
From Amyloid-β interrupts canonical Sonic hedgehog signaling by distorting primary cilia structure (2018) · cites this paper as [11]
In the citing paper
“Similar to PSEN1 , PSEN2 mutations may also cause increased production of long A 𝛃 peptide species (481, 523), although this needs more investigation.”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [523]
In the citing paper
“It is well established that this mutation causes concomitant increases in secreted A42 and A40 (Cai et al., 1993;Citron et al., 1994;Scheuner et al., 1996).”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Scheuner et al., 1996
In the citing paper
“In a previous study of human plasma (Scheuner et al., 1996), we showed that the Swedish APP K670N,M671L mutation increases both A42 and A40 and that other FAD-linked APP, PS1, and PS2 mutations selectively increase A42.”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Scheuner et al., 1996
In the citing paper
“In that report, we suggested that cerebral A deposition in FAD occurs because of an increase in CNS A that develops as part of a generalized genetic effect that also increases plasma A.”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Scheuner et al., 1996
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Self-citationCloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051
Self-citationCandidate gene for the chromosome 1 familial Alzheimer’s disease locus
Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D. M., Oshima, J., Pettingell, W. H., Yu, C.-E., Jondro, P. D., Schmidt, S. D., Wang, K., et al. (1995) · Science · doi:10.1126/science.7638622 · Cited by 2,577
Self-citationJarrett, J. T., & Lansbury, P. T. (1993) · Cell · doi:10.1016/0092-8674(93)90635-4 · Cited by 2,178
Rogaev, E. I., Sherrington, R., Rogaeva, E. A., Levesque, G., Ikeda, M., Liang, Y., Chi, H., Lin, C., Holman, K., Tsuda, T., et al. (1995) · Nature · doi:10.1038/376775a0 · Cited by 2,052
Self-citationJarrett, J. T., Berger, E. P., & Lansbury, P. T. (1993) · Biochemistry · doi:10.1021/bi00069a001 · Cited by 2,022
Amyloid β-peptide is produced by cultured cells during normal metabolism
Haass, C., Schlossmacher, M. G., Hung, A. Y., Vigo-Pelfrey, C., Mellon, A., Ostaszewski, B. L., Lieberburg, I., Koo, E. H., Schenk, D., Teplow, D. B., et al. (1992) · Nature · doi:10.1038/359322a0 · Cited by 1,921
Self-citationCitron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A. Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I., & Selkoe, D. J. (1992) · Nature · doi:10.1038/360672a0 · Cited by 1,757
Self-citationIsolation and quantification of soluble Alzheimer's β-peptide from biological fluids
Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schiossmacher, M., Whaley, J., Swindlehurst, C., et al. (1992) · Nature · doi:10.1038/359325a0 · Cited by 1,731
Self-citation
Cited by
Items 601–700 of 2,576
Characteristics of thein VitroVasoactivity of β-Amyloid Peptides
Crawford, F., Suo, Z., Fang, C., & Mullan, M. (1998) · Experimental Neurology · doi:10.1006/exnr.1997.6743 · Cited by 112
Sundelöf, J., Giedraitis, V., Irizarry, M. C., Sundström, J., Ingelsson, E., Rönnemaa, E., Ärnlöv, J., Gunnarsson, M. D., Hyman, B. T., Basun, H., et al. (2008) · Archives of Neurology · doi:10.1001/archneurol.2007.57 · Cited by 113
Self-citationArchitecture of the Alzheimer?s A�P Ion Channel Pore
Arispe, N. J. (2004) · The Journal of Membrane Biology · doi:10.1007/s00232-003-0638-7 · Cited by 127
Walter, J., Schindzielorz, A., Grünberg, J., & Haass, C. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.4.1391 · Cited by 111
Early-Onset Alzheimer Disease Caused by a New Mutation (V717L) in the Amyloid Precursor Protein Gene
Murrell, J. R., Hake, A. M., Quaid, K. A., Farlow, M. R., & Ghetti, B. (2000) · Archives of Neurology · doi:10.1001/archneur.57.6.885 · Cited by 111
Amyloid-β-Induced Dysregulation of AMPA Receptor Trafficking
Guntupalli, S., Widagdo, J., & Anggono, V. (2016) · Neural Plasticity · doi:10.1155/2016/3204519 · Cited by 110
Petit, D., Fernández, S. G., Zoltowska, K. M., Enzlein, T., Ryan, N. S., O’Connor, A., Szaruga, M., Hill, E., Vandenberghe, R., Fox, N. C., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01518-6 · Cited by 120
Hock, C., Maddalena, A., Raschig, A., Müller-Spahn, F., Eschweiler, G., Huger, K., Hewer, I., Hampel, H., Müller-Thornsen, T., Oertel, W., et al. (2003) · Amyloid · doi:10.3109/13506120308995249 · Cited by 112
Koch, P., Tamboli, I. Y., Mertens, J., Wunderlich, P., Ladewig, J., Stüber, K., Esselmann, H., Wiltfang, J., Brüstle, O., & Walter, J. (2012) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.02.012 · Cited by 129
Presenilin-1 uses phospholipase D1 as a negative regulator of β-amyloid formation
Cai, D., Netzer, W. J., Zhong, M., Lin, Y., Du, G., Frohman, M., Foster, D. A., Sisodia, S. S., Xu, H., Gorelick, F. S., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510708103 · Cited by 111
Nyabi, O., Bentahir, M., Horré, K., Herreman, A., Gottardi-Littell, N., Van Broeckhoven, C., Merchiers, P., Spittaels, K., Annaert, W., & De Strooper, B. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m306957200 · Cited by 110
Prevalence, incidence and duration of Braak's stages in the general population: can we know?
Duyckaerts, C., & Hauw, J.-J. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00047-x · Cited by 109
The brain RAS and Alzheimer's disease
Wright, J. W., & Harding, J. W. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.09.012 · Cited by 116
Deng, Y., Wang, Z., Wang, R., Zhang, X., Zhang, S., Wu, Y., Staufenbiel, M., Cai, F., & Song, W. (2013) · European Journal of Neuroscience · doi:10.1111/ejn.12235 · Cited by 108
“…processing of APP, giving rise to increased production of Ab, or a 42 amino acid form of Ab with a high propensity for plaque formation, implying a role for altered APP processing in the pathogenesis of FAD (Goate et al., 1991; Citron et al., 1992, 1997; Suzuki et al., 1994; Scheuner et al., 1996).”
BackgroundIncreased plasma amyloid β protein 1–42 levels in Down syndrome
Mehta, P. D., Dalton, A. J., Mehta, S. P., Kim, K. S., Sersen, E. A., & Wisniewski, H. M. (1998) · Neuroscience Letters · doi:10.1016/s0304-3940(97)00966-x · Cited by 108
Minogue, A. M., Jones, R. S., Kelly, R. J., McDonald, C., Connor, T. J., & Lynch, M. A. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.12.026 · Cited by 119
Bi, X., Gall, C. M., Zhou, J., & Lynch, G. (2002) · Neuroscience · doi:10.1016/s0306-4522(02)00132-x · Cited by 92
Yang, D.-S., Small, D. H., Seydel, U., Smith, J. D., Hallmayer, J., Gandy, S. E., & Martins, R. N. (1999) · Neuroscience · doi:10.1016/s0306-4522(98)00561-2 · Cited by 76
Synaptic Dysfunction in Alzheimer’s Disease
Marcello, E. E., Epis, R., Saraceno, C., & Luca, M. D. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-3-7091-0932-8_25 · Cited by 125
Genetics of Alzheimer disease in the pre- and post-GWAS era
Ertekin-Taner, N. (2010) · Alzheimer's Research & Therapy · doi:10.1186/alzrt26 · Cited by 106
Familial Alzheimer’s Disease Mutations in Presenilin Generate Amyloidogenic Aβ Peptide Seeds
Veugelen, S., Saito, T., Saido, T. C., Chávez‐Gutiérrez, L., & Strooper, B. D. (2016) · Neuron · doi:10.1016/j.neuron.2016.03.010 · Cited by 130
Nath, A., Hall, E., Tuzova, M., Dobbs, M., Jones, M., Anderson, C., Woodward, J. G., Guo, Z., Fu, W., Kryscio, R. J., et al. (2003) · NeuroMolecular Medicine · doi:10.1385/nmm:3:1:29 · Cited by 120
Walter, J., Grünberg, J., Capell, A., Pesold, B., Schindzielorz, A., Citron, M., Mendla, K., George-Hyslop, P. S., Multhaup, G., Selkoe, D. J., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.10.5349 · Cited by 108
Self-citationBACE (β-secretase) modulates the processing of APLP2 in vivo
Pastorino, L., Ikin, A. F., Lamprianou, S., Vacaresse, N., Revelli, J. P., Platt, K., Paganetti, P., Mathews, P. M., Harroch, S., & Buxbaum, J. D. (2004) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2003.12.013 · Cited by 84
Cell‐free assays for γ‐secretase activity
McLendon, C., Xin, T., Ziani-Cherif, C., Murphy, M. P., Findlay, K. A., Lewis, P. A., Pinnix, I., Sambamurti, K., Wang, R., Fauq, A., et al. (2000) · The FASEB Journal · doi:10.1096/fj.00-0286fje · Cited by 107
Levesque, G., Yu, G., Nishimura, M., Zhang, D. M., Levesque, L., Yu, H., Xu, D., Liang, Y., Rogaeva, E., Ikeda, M., et al. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0720999.x · Cited by 107
“…PS2 alter the proteolytic cleavage ofbAPP such that there is a relative increase in the production of longer b-amyloid peptide (Ab) derivatives, i.e., an increase in the ratio of Ab42/Ab40 (Martins et al., 1995; Borchelt et al., 1996; Duff et al., 1996; Scheuner et al., 1996; Citron et al., 1997).”
BackgroundRedox proteomics and amyloid β-peptide: Insights into Alzheimer disease
Butterfield, D. A., & Boyd‐Kimball, D. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14589 · Cited by 105
“…mutations that lead to familial AD (FAD) involve the genes encoding presenilin-1 or presenilin-2, which comprise the catalytic element of c-secretase, or APP and all subsequently increase the production of Ab(1–42) (Jarrett et al. 1993; Scheuner et al. 1996; Selkoe 2001; Goate and Hardy 2012).”
BackgroundConn, K. A., Borsom, E. M., & Cope, E. K. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2371950 · Cited by 115
“58 These insoluble peptides aggregate in the brain, forming amyloid-β plaques, and are associated with neurotoxicity.”
BackgroundEvin, G. M., Sernee, M. F., & Masters, C. L. (2006) · CNS Drugs · doi:10.2165/00023210-200620050-00002 · Cited by 119
Chen, F., Gu, Y., Hasegawa, H., Ruan, X., Arawaka, S., Fraser, P., Westaway, D., Mount, H., & St George-Hyslop, P. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m205093200 · Cited by 106
Dewachter, I., Van Dorpe, J., Smeijers, L., Gilis, M., Kuipéri, C., Laenen, I., Caluwaerts, N., Moechars, D., Checler, F., Vanderstichele, H., et al. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-17-06452.2000 · Cited by 105
“…mutant presenilins that cause familial early-onset AD have been proposed to affect g-secretase activity (Borchelt et al., 1996; Duff et al., 1996; Scheuner et al., 1996; Borchelt et al., 1997; Citron et al., 1997; Holcomb et al., 1998), we tested the hypothesis that aging disturbed APP…”
BackgroundThe Role of Adenosine in Alzheimers Disease
Rahman, A. (2009) · Current Neuropharmacology · doi:10.2174/157015909789152119 · Cited by 120
Plasma levels of amyloid β-protein 42 are increased in women with mild cognitive impairment
Assini, A., Cammarata, S., Vitali, A., Colucci, M., Giliberto, L., Borghi, R., Inglese, M. L., Volpe, S., Ratto, S., Dagna-Bricarelli, F., et al. (2004) · Neurology · doi:10.1212/01.wnl.0000137040.64252.ed · Cited by 104
Sugarman, M. C., Yamasaki, T. R., Oddo, S., Echegoyen, J. C., Murphy, M. P., Golde, T. E., Jannatipour, M., Leissring, M. A., & LaFerla, F. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.082545599 · Cited by 105
Yogev‐Falach, M., Amit, T., Bar‐Am, O., Weinstock, M., & Youdim, M. B. H. (2002) · The FASEB Journal · doi:10.1096/fj.02-0198fje · Cited by 104
Kurt, M. (2003) · Neurobiology of Disease · doi:10.1016/s0969-9961(03)00084-6 · Cited by 105
Genetics, Transcriptomics, and Proteomics of Alzheimers Disease
Papassotiropoulos, A., Fountoulakis, M., Dunckley, T., Stephan, D. A., & Reiman, E. M. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0418 · Cited by 105
Review: Model Peptides and the Physicochemical Approach to β-Amyloids
Lynn, D. G., & Meredith, S. C. (2000) · Journal of Structural Biology · doi:10.1006/jsbi.2000.4287 · Cited by 114
A Sensitive and Quantitative Assay for Measuring Cleavage of Presenilin Substrates
Karlström, H., Bergman, A., Lendahl, U., Näslund, J., & Lundkvist, J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.c100649200 · Cited by 105
Aisen, P. S. S. (2005) · CNS Drugs · doi:10.2165/00023210-200519120-00002 · Cited by 114
Rueeger, H., Lueoend, R. M., Rogel, O., Rondeau, J., Möbitz, H., Machauer, R., Jacobson, L. H., Staufenbiel, M., Desrayaud, S., & Neumann, U. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300069y · Cited by 110
Specific Compositions of Amyloid-β Peptides as the Determinant of Toxic β-Aggregation
Yoshiike, Y., Chui, D.-H., Akagi, T., Tanaka, N., & Takashima, A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m212785200 · Cited by 102
Lamb, B. T., Bardel, K. A., Kulnane, L. S., Anderson, J. J., Holtz, G., Wagner, S. L., Sisodia, S. S., & Hoeger, E. J. (1999) · Nature Neuroscience · doi:10.1038/11154 · Cited by 114
Subasinghe, S., Unabia, S., Barrow, C. J., Mok, S. S., Aguilar, M., & Small, D. H. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01552.x · Cited by 101
“Production of these minor forms is closely linked to AD pathogenesis (Scheuner et al. 1996).”
BackgroundKim, S.-H., Leem, J. Y., Lah, J. J., Slunt, H. H., Levey, A. I., Thinakaran, G., & Sisodia, S. S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m108245200 · Cited by 102
Additive Effects of PS1 and APP Mutations on Secretion of the 42-Residue Amyloid β-Protein
Citron, M., Eckman, C. B., Diehl, T. S., Corcoran, C., Ostaszewski, B. L., Xia, W., Levesque, G., St. George Hyslop, P., Younkin, S. G., & Selkoe, D. J. (1998) · Neurobiology of Disease · doi:10.1006/nbdi.1998.0183 · Cited by 101
“This was first found in plasma and fibroblast conditioned media of PS1 and PS2 mutation carriers, indicating that the presenilin mutations have a systemwide effect (Scheuner et al., 1996).”
BackgroundSelf-citationIncreased Aβ42(43) from cell lines expressing presenilin 1 mutations
Mehta, N. D., Refolo, L. M., Eckman, C., Sanders, S., Yager, D., Perez‐Tur, J., Younkin, S., Duff, K., Hardy, J., & Hutton, M. (1998) · Annals of Neurology · doi:10.1002/ana.410430217 · Cited by 101
Self-citationAPPswe/Aβ regulation of osteoclast activation and RAGE expression in an age-dependent manner
Cui, S., Xiong, F., Hong, Y., Jung, J.-U., Li, X.-S., Liu, J.-Z., Yan, R., Mei, L., Feng, X., & Xiong, W.-C. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.299 · Cited by 101
López‐Ortiz, S., Pinto-Fraga, J., Valenzuela, P. L., Martín-Hernández, J., Seisdedos, M. M., García, Ó., Toschi, N., Giuliano, F. D., Garaci, F. G., Mercuri, N. B., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062897 · Cited by 115
Biomarkers of Alzheimer Disease
Growdon, J. H. (1999) · Archives of Neurology · doi:10.1001/archneur.56.3.281 · Cited by 101
Metabolism of amyloid β peptide and pathogenesis of Alzheimer's disease
Saido, T. C., & Iwata, N. (2006) · Neuroscience Research · doi:10.1016/j.neures.2005.12.015 · Cited by 112
Urano, T., & Tohda, C. (2010) · Phytotherapy Research · doi:10.1002/ptr.3183 · Cited by 101
“The production of Aβ is promoted by the mutation of APP and/ or presenilin 1 (PS1), and several mutation sites in familial AD patients were reported (Scheuner et al., 1996; Russo et al., 2000).”
BackgroundWinkler, E., Kamp, F., Scheuring, J., Ebke, A., Fukumori, A., & Steiner, H. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.356659 · Cited by 101
“Few FADmutations have also been found in APP, most of them are located in the APP TMD at the -secretase cleavage sites and increase the ratio of A 42 to total A (15).”
BackgroundMutations in RNA: a first example of molecular misreading in Alzheimer's disease
van Leeuwen, F. W., Hol, E. M., & Burbach, J. P. H. (1998) · Trends in Neurosciences · doi:10.1016/s0166-2236(98)01280-6 · Cited by 106
Genetic Factors in the Genesis of Alzheimer's Disease
ST GEORGE‐HYSLOP, P. H. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb05552.x · Cited by 101
Presenilin structure, function and role in Alzheimer disease
Fraser, P. E., Yang, D.-S., Yu, G., Lévesque, L., Nishimura, M., Arawaka, S., Serpell, L. C., Rogaeva, E. A., & George‐Hyslop, P. S. (2000) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(00)00028-4 · Cited by 118
Xie, Y., Ba, L., Wang, M., Deng, S., Chen, S., Huang, L., Zhang, M., Wang, W., & Ding, F. (2020) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13218 · Cited by 97
Amyloid‐β oligomers are inefficiently measured by enzyme‐linked immunosorbent assay
Stenh, C., Englund, H., Lord, A., Johansson, A., Almeida, C. G., Gellerfors, P., Greengard, P., Gouras, G. K., Lannfelt, L., & Nilsson, L. N. G. (2005) · Annals of Neurology · doi:10.1002/ana.20524 · Cited by 99
Self-citationApolipoprotein E, amyloid-beta, and neuroinflammation in Alzheimer’s disease
Dorey, E., Chang, N., Liu, Q. Y., Yang, Z., & Zhang, W. (2014) · Neuroscience Bulletin · doi:10.1007/s12264-013-1422-z · Cited by 116
Moving beyond amyloid and tau to capture the biological heterogeneity of Alzheimer’s disease
Young‐Pearse, T. L., Lee, H., Hsieh, Y., Chou, V., & Selkoe, D. J. (2023) · Trends in Neurosciences · doi:10.1016/j.tins.2023.03.005 · Cited by 107
Self-citationPresenilins interact with Rab11, a small GTPase involved in the regulation of vesicular transport
Dumanchin, C. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.7.1263 · Cited by 99
Presenilins are not required for Aβ42 production in the early secretory pathway
Wilson, C., Doms, R. W., Zheng, H., & Lee, V. M. ‐. (2002) · Nature Neuroscience · doi:10.1038/nn898 · Cited by 111
“Alzheimer’s Aβ (1-42) is generated in the endoplasmic reticulum/intermediate compartment of NT2N cells.”
Ringman, J. M., Monsell, S., Ng, D. W., Zhou, Y., Nguyen, A., Coppola, G., Van Berlo, V., Mendez, M. F., Tung, S., Weintraub, S., et al. (2016) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlv028 · Cited by 99
Aβ40 Protects Non-toxic Aβ42 Monomer from Aggregation
Yan, Y., & Wang, C. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.04.014 · Cited by 99
Golde, T. E. (2006) · Brain Pathology · doi:10.1111/j.1750-3639.2005.tb00104.x · Cited by 99
Fukuchi, K.-I., Tahara, K., Kim, H., Maxwell, J., Lewis, T., Accavitti-Loper, M., Kim, H., Ponnazhagan, S., & Lalonde, R. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.04.012 · Cited by 84
“…in the etiology of familial AD, have been shown to increase Aβ production, particularly a longer form of Aβ consisting of 42 amino acids (Aβ1–42) (Scheuner et al., 1996); (2) Aβ1–42 is considered to be highly amyloidogenic and oligomeric forms of Aβ are neurotoxic (Lambert et al., 2001;…”
BackgroundHyman, B. T., Strickland, D., & Rebeck, G. W. (2000) · Archives of Neurology · doi:10.1001/archneur.57.5.646 · Cited by 101
Mean age of onset in familial Alzheimer's disease is determined by amyloid beta 42
Duering, M., Grimm, M. O. W., Grimm, H. S., Schröder, J., & Hartmann, T. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.08.002 · Cited by 112
Presenilins and Alzheimer's disease
Kim, T.-W., & Tanzi, R. E. (1997) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(97)80089-x · Cited by 97
“Recently, it was demonstrated that fibroblasts cultured from PS1 and PS2 mutant carriers secreted elevated amounts of As42 ( 41 ).”
BackgroundSelf-citationTalking Point on the role of presenilin mutations in Alzheimer disease
Strooper, B. D. (2007) · Cited by 97
Modulation of Disordered Proteins with a Focus on Neurodegenerative Diseases and Other Pathologies
Martinelli, A. H. S., Lopes, F. C., John, E. B. D. O., Carlini, C. R., & Ligabue‐Braun, R. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061322 · Cited by 105
Alzheimer’s disease: A clinical perspective and future nonhuman primate research opportunities
Haque, R. U., & Levey, A. I. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1912954116 · Cited by 103
Ryan, D. A., Narrow, W. C., Federoff, H. J., & Bowers, W. J. (2010) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2010.05.001 · Cited by 99
“Mutations in the genes encoding presenilin 1, 2 and amyloid precursor protein (APP) all effectively lead to an increase in the generation of the pro-amyloidogenic Aβ1–42 peptide species and eventually an early-onset familial form of AD (Scheuner et al., 1996).”
BackgroundNotarachille, G., Arnesano, F., Calò, V., & Meleleo, D. (2014) · BioMetals · doi:10.1007/s10534-014-9719-6 · Cited by 101
Neuronal intermediate filaments and neurodegenerative disorders
Perrot, R., & Eyer, J. (2009) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2009.06.004 · Cited by 125
Ertekin-Taner, N., Allen, M., Fadale, D., Scanlin, L., Younkin, L., Petersen, R. C., Graff-Radford, N., & Younkin, S. G. (2004) · Human Mutation · doi:10.1002/humu.20016 · Cited by 97
“[Janssens et al., 2001], making VR22 a strong functional candidate because b catenin interacts with presenilin 1, which has many mutations that increase Ab42 [Borchelt et al., 1996; Duff et al., 1996; Scheuner et al., 1996] and cause early-onset familial AD [Sherrington et al., 1995].”
BackgroundMethodSelf-citationGenetic Heterogeneity in Alzheimer Disease and Implications for Treatment Strategies
Dominantly Inherited Alzheimer Network, Ringman, J. M., Goate, A., Masters, C. L., Cairns, N. J., Danek, A., Graff-Radford, N., Ghetti, B., & Morris, J. C. (2014) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-014-0499-8 · Cited by 96
Vasciaveo, V., Iadarola, A., Casile, A., Dante, D., Morello, G., Minotta, L., Tamagno, E., Cicolin, A., & Guglielmotto, M. (2023) · Acta Neuropathologica Communications · doi:10.1186/s40478-022-01498-2 · Cited by 108
“Only a small proportion of AD cases are familial, which is determined by gene mutations in the amyloid precursor protein (APP), presenilin 1 (PS1), and presenilin 2 (PS2) leading to increased production of amyloid-β (Aβ) [2, 3].”
BackgroundProfiles of matrix metalloproteinases and their inhibitors in plasma of patients with dementia
Lorenzl, S., Büerger, K., Hampel, H., & Beal, M. F. (2007) · International Psychogeriatrics · doi:10.1017/s1041610207005790 · Cited by 96
“A major component of senile plaques is β-amyloid (Aβ), which is elevated not only in brain tissue but also in the blood of patients with AD (Scheuner et al., 1996).”
BackgroundIrie, K., Murakami, K., Masuda, Y., Morimoto, A., Ohigashi, H., Ohashi, R., Takegoshi, K., Nagao, M., Shimizu, T., & Shirasawa, T. (2005) · Journal of Bioscience and Bioengineering · doi:10.1263/jbb.99.437 · Cited by 123
Majercak, J., Ray, W. J., Espeseth, A., Simon, A., Shi, X.-P., Wolffe, C., Getty, K., Marine, S., Stec, E., Ferrer, M., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605461103 · Cited by 95
Biomarker-based dissection of neurodegenerative diseases
Olsson, B., Zetterberg, H., Hampel, H. J., & Blennow, K. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.04.006 · Cited by 108
Zhen, W., Han, H., Anguiano, M., Lemere, C. A., Cho, C., & Lansbury, P. T. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm990103w · Cited by 101
Presenilins function in ER calcium leak and Alzheimer's disease pathogenesis
Supnet, C., & Bezprozvanny, I. (2011) · Cell Calcium · doi:10.1016/j.ceca.2011.05.013 · Cited by 95
“…PS-FAD mutations result in a shift in the proteolysis of APP such that there is an increase in the production the hydrophobic, aggregation-prone 1–42 Aβ fragment, increasing Aβ42/40 ratio and contributing to Aβ plaque formation (De Strooper et al., 1998; Scheuner et al., 1996; Wolfe et al., 1999).”
BackgroundSeppala, T. T., Herukka, S.-K., Hanninen, T., Tervo, S., Hallikainen, M., Soininen, H., & Pirttila, T. (2010) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2010.205757 · Cited by 95
Rab GTPases: Switching to Human Diseases
Guadagno, N. A., & Progida, C. (2019) · Cells · doi:10.3390/cells8080909 · Cited by 106
Guillot‐Sestier, M., Sunyach, C., Ferreira, S. T., Marzolo, M., Bauer, C., Thevenet, A., & Checler, F. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.323626 · Cited by 109
“This cell systemwas chosen first because it leads to increased production of A (mainly A 42 (42)) and second because we previously established that this mutation triggers a drastic exacerbation of both STS-stimulated caspase-3 activation and p53-dependent cell death (38).”
BackgroundKaczorowski, C. C., Sametsky, E., Shah, S., Vassar, R., & Disterhoft, J. F. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.09.003 · Cited by 98
Intranasal therapeutic strategies for management of Alzheimer’s disease
Sood, S., Jain, K., & Gowthamarajan, K. (2014) · Journal of Drug Targeting · doi:10.3109/1061186x.2013.876644 · Cited by 95
Understanding the roles of mutations in the amyloid precursor protein in Alzheimer disease
Hunter, S., & Brayne, C. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.218 · Cited by 94
Aging sensitizes toward ROS formation and lipid peroxidation in PS1M146L transgenic mice
Schüssel, K., Frey, C., Jourdan, C., Keil, U., Weber, C. C., Müller-Spahn, F., Müller, W. E., & Eckert, A. (2005) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2005.10.041 · Cited by 100
The Solved and Unsolved Mysteries of the Genetics of Early-Onset Alzheimer 's Disease
Rogaeva, E. A. (2002) · NeuroMolecular Medicine · doi:10.1385/nmm:2:1:01 · Cited by 114
“…that changes in APP processing are central to AD pathology won further support after the discovery that mutations in the PSs interfere with the cleavage of APP, which causes the overproduction of the most destructive, highly amyloidogenic A 42 peptide (Scheuner et al., 1996; Citron et al., 1997).”
BackgroundArduengo, P. M., Appleberry, O. K., Chuang, P., & L’Hernault, S. W. (1998) · Journal of Cell Science · doi:10.1242/jcs.111.24.3645 · Cited by 98
Familial Alzheimer’s Disease Mutations Differentially Alter Amyloid β-Protein Oligomerization
Gessel, M. M., Bernstein, S., Kemper, M., Teplow, D. B., & Bowers, M. T. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn300050d · Cited by 95
Fukumori, A., & Steiner, H. (2016) · The EMBO Journal · doi:10.15252/embj.201694151 · Cited by 94
“This manifests in an increased ratio of A b 42 and A b 43 species over A b 40, the predominant A b species generated by c -secretase (Scheuner et al , 1996; Chavez-Gutierrez et al , 2012).”
3D mapping reveals network-specific amyloid progression and subcortical susceptibility in mice
Gail Canter, R., Huang, W.-C., Choi, H., Wang, J., Ashley Watson, L., Yao, C. G., Abdurrob, F., Bousleiman, S. M., Young, J. Z., Bennett, D. A., et al. (2019) · Communications Biology · doi:10.1038/s42003-019-0599-8 · Cited by 89
Lee, G., Pollard, H. B., & Arispe, N. J. (2002) · Peptides · doi:10.1016/s0196-9781(02)00060-8 · Cited by 109
De Jonghe, C., MarcCruts, Rogaeva, E. A., Tysoe, C., Singleton, A., Vanderstichele, H., Meschino, W., Dermaut, B., Vanderhoeven, I., Backhovens, H., et al. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.8.1529 · Cited by 93
Self-citationMurine models of brain aging and age-related neurodegenerative diseases
Jucker, M., & Ingram, D. K. (1997) · Behavioural Brain Research · doi:10.1016/s0166-4328(96)02243-7 · Cited by 101
Gama Sosa, M. A., Gasperi, R. D., Rocher, A. B., Wang, A. C.-J., Janssen, W. G. M., Flores, T., Perez, G. M., Schmeidler, J., Dickstein, D. L., Hof, P. R., et al. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.090482 · Cited by 92
Metadata
- Authors
- Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., Larson, E., Levy-Lahad, L., Viitanen, M., Peskind, E., Poorkaj, P., Schellenberg, G., Tanzi, R., Wasco, W., Lannfelt, L., Selkoe, D., & Younkin, S.
- Affiliations
- Case Western Reserve University (US)
- Mayo Clinic (US)
- Karolinska Institutet (SE)
- Brigham and Women's Hospital (US)
- Takeda (Japan) (JP)
- University of Washington (US)
- University of South Florida (US)
- Harvard University (US)
- ORCID
- Venue
- Nature Medicine
- Published
- 1996-08
- Volume
- 2
- Issue
- 8
- Pages
- 864-870
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2101077392
- Semantic Scholar
- ce2164647cb7fb8dcec21d95359a92ec9830047a
- Cited by
- 2,599
- References
- 40
- Citations by year
- 2026: 26 · 2025: 34 · 2024: 58 · 2023: 74 · 2022: 45 · 2021: 66 · 2020: 66 · 2019: 58 · 2018: 53 · 2017: 64 · 2016: 76 · 2015: 72 · 2014: 77 · 2013: 91 · 2012: 96
- FWCI
- 102.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- amyloid-beta, familial Alzheimer's disease, presenilin 1, presenilin 2, amyloid precursor protein, APP mutations, amyloid plaques
- MeSH terms
- Alzheimer Disease, Cells, Cultured, Female, Fibroblasts, Humans, Male, Membrane Proteins, Mutation, Peptide Fragments, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Culture Media, Conditioned, Presenilin-1, Presenilin-2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.